Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

NCT00664287 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: niacin (+) laropiprant
DRUG: placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC